GLP-1 for Fatty Liver and MASH: Wegovy Approval and Trials

Wegovy injection has a US indication for adults with noncirrhotic MASH and moderate-to-advanced fibrosis, consistent with stages F2–F3. That is more specific than “GLP-1 drugs treat fatty liver.” A fatty-liver finding alone does not establish the diagnosis, fibrosis stage or eligibility for this treatment. Current Wegovy prescribing information.

MASLD, MASH and cirrhosis are different

MASLD refers to metabolic dysfunction-associated steatotic liver disease. MASH is the form involving liver inflammation and injury; fibrosis describes scarring. Cirrhosis represents a more advanced stage and must not be treated as interchangeable with the noncirrhotic population in the Wegovy indication.

FDA describes MASH as a progressive disease that may lead to serious liver complications. The absence of obvious symptoms does not establish that the liver is unaffected. FDA explanation.

What the Wegovy approval means

The MASH indication received accelerated approval in August 2025 based on improvements in liver-biopsy outcomes. Confirmation of clinical benefit, such as fewer serious liver events, remains distinct from showing improved biopsy findings. FDA approval and evidence summary.

Wegovy was not the first medication approved for this liver condition. FDA approved resmetirom, marketed as Rezdiffra, in March 2024 for adults with noncirrhotic NASH/MASH and moderate-to-advanced fibrosis. Resmetirom is not a GLP-1 receptor agonist. FDA Rezdiffra trial snapshot.

What ESSENCE measured

The planned interim analysis of the phase 3 ESSENCE trial included the first 800 participants, evaluated at 72 weeks. It studied semaglutide 2.4 mg weekly in people with biopsy-defined MASH and F2–F3 fibrosis. Primary report.

Biopsy outcome at week 72	Semaglutide	Placebo
MASH resolution without worsening fibrosis	62.9%	34.3%
Fibrosis improvement without worsening MASH	36.8%	22.4%

These outcomes are not equivalent to a proven reduction in liver transplantation or death. They also do not show that all participants became free of liver disease. The ongoing study follows longer-term clinical outcomes. Trial report; FDA discussion.

What about tirzepatide?

The phase 2 SYNERGY-NASH trial randomized 190 participants with MASH and F2–F3 fibrosis. At 52 weeks, MASH resolution without worsening fibrosis was reported in 44%, 56% and 62% of the tirzepatide 5, 10 and 15 mg groups, respectively, versus 10% with placebo. Original trial.

Those findings support further study. They cannot be compared directly with ESSENCE percentages to rank the drugs: trial populations, follow-up and analysis differ. The current US Mounjaro and Zepbound labels do not establish tirzepatide as an approved MASH treatment.

Our tirzepatide and retatrutide comparison explains the same distinction between promising research and regulatory approval.

Questions for a liver-care appointment

• Is the diagnosis MASLD, MASH or another cause of liver disease?
• How was fibrosis assessed, and is cirrhosis present?
• Which treatment options fit the actual diagnosis and other health conditions?
• What would count as a useful response, and how will it be measured?
• Which adverse effects or new symptoms need prompt contact?

Drug selection and monitoring belong within that assessment. A change in body weight or a single liver-enzyme result should not be presented as proof that fibrosis has resolved.

Gallbladder disease is a separate concern with some GLP-1 therapies; see our gallbladder risk and symptom guide. Pregnancy also requires a specific benefit-risk discussion, covered in the pregnancy-planning explainer.

Sources and revision

Sources checked September 15, 2026. This update corrects the “first approved treatment” claim, narrows the Wegovy indication, separates biopsy endpoints from clinical outcomes and removes unsupported class-wide fibrosis and cirrhosis claims. Prepared by the editorial team with AI assistance; no independent hepatology review is claimed.